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Available online 12 September 2016Background: Type D personality has been associated with adverse outcomes in patients with coronary artery
disease (CAD). However, large heterogeneity exists between Type D studies, including some studies reporting
null-ﬁndings.
Objectives: The aim of this studywas to examine i) choice of endpoint and ii) age as two study characteristics that
may partly explain this large heterogeneity in the Type D associated prognostic effect.
Methods:Weused four existing data cohorts of 1503 CADpatients (89%male,mean age=57.2±9.1)with base-
linemeasures of TypeD and endpoints N5 years follow-up:major adverse cardiac events (MACE), cardiac death/MI,
and non-cardiac death. Patients were classiﬁed in 4 age categories: b50 y, 50–59 y, 60–69 y and ≥70 y. Multiple
logistic regression models included age, sex, and clinical covariates.
Results: At follow-up, there were 295 events, including 116 cardiac death/MI, and 37 non-cardiac deaths. Both
continuous and categorical measures of Type D predicted adverse events. Type D was independently associated
withMACE (OR= 1.82; 95%CI 1.33–2.50) and cardiac death/MI (OR= 2.49; 95%CI 1.55–3.99). However, Type D
was not associated with non-cardiac death (OR = 1.23; 95%CI 0.57–2.69). Regarding age, Type D consistently
predicted MACE in the lower age groups (all ORs ≥ 2.20, all ps ≤ .004), but not in patients aged ≥70 y (OR =
1.43, p = .57).
Conclusions: Choice of endpoint and agemodulated the risk conferred by Type D personality. Type Dwas associated
with an increased risk of cardiac events, but not with non-cardiac death, or with events in patients aged ≥70 y. Re-
search on psychosocial risk in CAD should account for different sources of heterogeneity in study characteristics.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Moderators1. Introduction
Cardiovascular disease is a leading cause of death in the Western
world, with coronary artery disease (CAD) being the major culprit.
Even though mortality rates have dropped signiﬁcantly over the past
decade, owing to improved treatment and reduced post-infarctionmor-
tality, it is important to even further reduce this event rate [1]. Besides
classical risk factors, psychological factors such as emotional distress
have emerged as potent risk factors as well. In addition to depression
[2], other psychosocial factors such as anxiety [3] and personality traits
[4,5] have also shown to be important in risk stratiﬁcation for CAD
prognosis. A fairly large body of research has examined the association
of Type D personality (i.e. the general tendency towards emotional
distress characterized by high scores on social inhibition and negative
affectivity traits) with prognosis in patients with cardiovascular disease
[6].nd Clinical Psychology, Tilburg
nds.
Kupper).
land Ltd. This is an open access articlSeveral recent meta-analyses [7–9] have indicated that Type D is
associated with an approximately doubled risk of adverse events and
mortality, predominantly in patients with coronary artery disease
(CAD). However, these meta-analyses reported large heterogeneity be-
tween studies [7–9], and negative ﬁndings have been reported in Type
D studies that used all-cause mortality as an endpoint in patients with
CAD [10] and heart failure [11–13]. Therefore, a better understanding
of when and how Type D inﬂuences cardiovascular prognosis and
other adverse outcomes is needed to explain the observed heterogene-
ity in studies [7], and mixed ﬁndings regarding prognosis [14].
Most human illnesses, CAD alike, are etiologically complex, with
multiple interacting factors inﬂuencing illness incidence and prognosis
[15]. These factorsmay also alter the effect of psychosocial riskmarkers,
such as Type D, in different subgroups. To avoid spurious ﬁndings,
subgroup analyses need to be pre-speciﬁed, and based on theory and
biobehavioral disease processes [16]. Heterogeneity analysis in the
most recent meta-analysis showed that disease stage (CAD vs. heart
failure) was one source of heterogeneity [7]. There are at least two
other factors that may explain part of the heterogeneity observed in
the prognostic effects of Type D personality, i.e., the choice of endpoint
and age.e under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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effect of a risk factor [17]. While Type D studies reporting null ﬁndings
focused on all-cause mortality [10–13], positive studies also used cardi-
ac endpoints [7], suggesting that Type D may be more related to fatal
and non-fatal cardiac events [14]. Others showed that social avoidance
(a trait that is closely related to Type D) predicted cardiac death but
not non-cardiac death [18]. The age composition of the sample is anoth-
er potential effect modiﬁer, and thus a potential explanation for hetero-
geneity in ﬁndings. The risk of adverse events is already higher in older
patients due to an aging heart [19–21], and older age is included in the
Euroscore-II and Framingham risk scores. Preliminary data showed that
the adverse effect of Type D was more pronounced in younger than in
older patients [22], suggesting that the risk conferred by Type D may
change with age. Moreover, age-associated conditions, such as kidney
disease, anemia, frailty, and cognitive dysfunction, have prognostic im-
pact, explaining a substantial part of the variance inmortality risk in the
relatively older age groups [23]. Therefore, the current individual
patient-based re-examination of four consecutive cohorts of CAD
patients [24–27] will examine whether choice of endpoint and age can
explain heterogeneity in the prognostic effect of Type D personality.
2. Methods
2.1. Patients
This paper reports on 1503 patients with CAD (89%men; mean age:
57.2± 9.1 years) from the Antwerp cardiac rehabilitation programwho
were enrolled during 4 consecutive primary studies: 303 patients in the
1st cohort (1985–88) [24], 322 in the 2nd cohort (1989–92) [25], 337 in
the 3rd cohort (1993–97) [26] and 541 in the 4th cohort (1998–2005)
[27]. Methodological details have been described previously [24–27]. At
baseline, patients providedwritten informed consent and completedper-
sonality measures. Patients with other major conditions (e.g., cancer)
were excluded. This study was approved by the Medical Ethics Commit-
tee of the University Hospital Antwerp (protocol 5/48/193).
2.2. Type D personality
Social inhibition and negative affectivity were assessed in each co-
hort [24–27], with slight differences between cohorts. In theﬁrst cohort,
the inhibition scale of the Heart Patients Psychological Questionnaire
(HPPQ) and the State-Trait Anxiety Inventory (STAI) were used [24],
while the DS-16, developed based on previously mentioned question-
naires, (Cohort 2 & 3; [28]) and DS14 (Cohort 4; [29]) were used in sub-
sequent cohorts. The use of different measures was unrelated to Type D
prevalence rates (p= 0.54) and did not alter associations with adverse
events across the 4 cohorts (p = 0.55), which justiﬁed the pooling of
data across Type D measures used in the different cohorts.
Type D can be assessed as a continuous (negative affectivity x social
inhibition interaction) or categorical (categories based on high/low trait
levels) variable [27,30]. Social inhibition and negative affectivity scores
of these measures were transformed to standardized Z scores (mean=
0; standard deviation = 1) in analyses using continuous measures of
Type D. As there are arguments in favor of both approaches, we used
both to examine the prognostic value of Type D. For the categorical
analyses, previously published cut-off scores on negative affectivity
and social inhibition scales [24,28,29] were used to construct 4 groups:
a) low negative affectivity/low inhibition, b) low negative affectivity/
high inhibition, c) high negative affectivity/low inhibition and d) high
negative affectivity/high inhibition.
2.3. End points
The follow-up interval was on average 8 years in the 1st cohort [24]
and 5 years in the subsequent cohorts [24–26]. Information on mortal-
ity, nonfatal MI and CABG/PCI was extracted from hospital records andthe patient's attending physician was involved in the classiﬁcation of
cause of death. Survival status was conﬁrmed through telephone con-
tact with all participants or their families. We used three endpoints.
The ﬁrst end pointwasmajor adverse cardiac events (MACE; a compos-
ite of death, MI, CABG, PCI or progression of CAD as documented by an-
giography). The second end point was cardiac death or MI as a rigorous
measure of cardiac prognosis. Finally, we examined the associationwith
non-cardiac death, which was deﬁned as all other, non-cardiac, natural
causes of death.
2.4. Subgroup analyses
We examined the effect of Type D in two pre-speciﬁed subgroup
analyses that were based on i) choice of endpoint (as described
above) and ii) age. With respect to age, we made four subgroups,
representing patients aged below 50 years (n = 299), between
50–59 years (n = 569), between 60–69 years (n = 522) and 70 years
or older (n = 113), inspired by the potentially differential etiology
and prognostic risks associated with the younger and older age groups
[19–22].
2.5. Covariates
The covariates that proved to be signiﬁcantly related to adverse
events in the four original reports [24–27] were used in the current
analysis, including age, sex, index MI, and CABG/PCI at baseline, left
ventricular ejection fraction (LVEF) [31] and physical ﬁtness [32]. Poor
physical ﬁtness was deﬁned by a median split for peak work load on
an exercise test (≤140 and ≤120 W for men aged ≤55 y/≥56 y; ≤100
and ≤80 W for women aged ≤55 y/≥56 y) [25].
2.6. Statistical analyses
Because the older cohorts [24,25] may differ medically due to ad-
vancements in medical treatment, we ﬁrst compared patients that
were enrolled between 1985–1994 (N = 742) and between 1995–
2005 (N = 761) to examine any differences in end points, covariates
and Type D personality traits. For this purpose, we used Pearson chi
square tests for categorical variables and Student t-tests for continuous
variables.
Three hierarchical multiple logistic regressions were performed to
assess the association of Type D personality with MACE, cardiac death/
MI, and non-cardiac death as separate end points We performed these
analyses twice, once for the continuous Type D measure (interaction
of NA and SI z sores) adjusting for the main NA and SI effects [30], and
once for the categorized Type D measure in which the low NA/lowSI
category was used as a reference.
To examine the age effects, for each age subgroup, hierarchical mul-
tiple logistic regressions were performed with MACE (including cardiac
death) as outcome variable. In all regression models, Type D variables
were entered together with a priori deﬁned covariates. SPSS 19 (IBM
SPSS Statistics for Windows, Version 19.0. Armonk, NY) was used for
all analyses and a p value of .05 was considered signiﬁcant.
3. Results
3.1. Adverse events
There were 295 patients who experienced an adverse event, includ-
ing 93deaths. All deathswere attributable to natural causes, ofwhich 56
were considered cardiac deaths and 37 non-cardiac deaths (18 due to
cancer and 19 due to other natural causes). Non-fatal events included
(recurrent) non-fatal MI (n= 60), CABG (n= 44), PCI (n= 120), and
CAD progression on angiography (n= 12).
Table 1
Sample characteristics for total sample, and stratiﬁed by sample cohort.
Total
(N=1503)
1985–1994
cohort
(N=742)
1995-2005
cohort
(N=761)
P
value
Demographics
Age Mean ± SD 57.2 ± 9.1 56.0 ± 7.9 58.3 ± 9.9 b .0001
Male sex 1334 (89%) 669 (90%) 665 (87%) .088
Clinical variables
Index MI at baseline 731 (49%) 390 (53%) 341 (45%) .003
CABG at baseline 820 (55%) 450 (61%) 370 (49%) b .0001
PCI at baseline 415 (28%) 107 (14%) 308 (41%) b .0001
Decreased LVEF (b50%) 332 (22%) 131 (18%) 201 (26%) b .0001
Poor exercise tolerance* 555 (37%) 244 (33%) 311 (41%) .001
Medication use
Aspirin 1228 (82%) 551 (74%) 677 (89%) b .0001
Beta-blocker† 966 (65%) 395 (53%) 571 (76%) b .0001
ACE inhibitor/ARB† 387 (26%) 68 (9%) 319 (43%) b .0001
Personality
High NA only 242 (16%) 119 (16%) 123 (16%) .95
High SI only 303 (20%) 162 (22%) 141 (19%) .11
Type D personality 451 (30%) 223 (30%) 228 (30%) .97
Adverse events
MACE 295 (19%) 150 (20%) 145 (19%) .57
Cardiac death/MI 116 (8%) 59 (8%) 57 (8%) .74
Non-cardiac death 37 (2.5%) 18 (2.4%) 19 (2.5%) .93
Numbers are presented as N (%) unless otherwise indicated. CABG= coronary artery by-
pass surgery; MACE = major adverse cardiac event; MI = myocardial infarction; PCI =
percutaneous coronary intervention.
⁎≤140/≤120 W for men; ≤100/≤80 W for women; † N= 1489
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Comparing the cohorts of patients recruited in 1985–1994 (n =
742) and in 1995–2005 (n = 761) showed that the prevalence of
Type D personality was 30% in both cohorts (Table 1). With respect to
treatment, there were large differences, as could be expected, due to
medical advancements over the past 30 years. There was a decrease in
CABG, and an increase in PCI, aspirin, beta blocker, and ACE-inhibitor
use. However, the interaction between Type D and cohort (1985–1994
vs 1995–2005) was not signiﬁcant in the prediction of MACE (OR =
0.78; 95%CI 0.046–1.32, p= .35), indicating that cohort-related changes
in cardiac treatment did not alter the association of TypeDwith adverseTable 2
Risk estimates for MACE, cardiac death/MI and non-cardiac death.⁎
MACE
(n = 295)
OR [95% CI] p
Clinical covariates
Age 0.99 [0.98–1.01] .26
Male sex 0.98 [0.65–1.49] .94
Index MI at baseline 0.93 [0.68–1.28] .66
Decreased LVEF (b50%) 1.46 [1.07–1.98] .015
Poor exercise tolerance 1.76 [1.33–2.32] b .0001
CABG at baseline 0.40 [0.28–0.57] b .0001
PCI at baseline 0.79 [0.57–1.11] .18
Continuous Type D measures
Negative affectivity (NA z score) 1.13 [0.98–1.30] .093
Social inhibition (SI z score) 1.07 [0.92–1.23] .39
NA x SI interaction (Type D) 1.24 [1.09–1.39] .001
CABG= coronary artery bypass surgery; MACE=major adverse cardiac event; MI =myocard
social inhibition.
1Left ventricular ejection fraction ≤50%.
2≤140/≤120 W for younger/older men; ≤100/≤80 W for younger/older women.
⁎ Multivariable logistic regression models with all variables entered simultaneously. Bold: sievents. Type D was associated with an increased risk of MACE (ORcohort
1 = 2.60; 95%CI 1.80–3.77; ORcohort 2 = 2.03; 95%CI 1.39–2.94), and
cardiac death/MI (ORcohort 1 = 3.56; 95%CI 2.07–6.12 and ORcohort 2 =
2.63; 95%CI 1.53–4.53), respectively. So, despitemedical advancements,
Type D seems to have a relatively stable prognostic effect across these
cohorts, justifying merging of all cohorts into one.
3.3. Different endpoint as a source of heterogeneity
The continuous Type D score as measured by the interaction of
negative affectivity and social inhibition scales was associated with an
increased risk of MACE (p = .001) and cardiac death/MI (p = .01)
after adjustment for statistical covariates and the main trait effects of
negative affectivity and social inhibition (Table 2). LVEF≤50%, decreased
physical ﬁtness and no CABG at baseline were also independent predic-
tors of MACE and cardiac death/MI. In contrast, Type D personality was
not associated with non-cardiac causes of death (Table 2, last column).
In fact, LVEF, CABG and PCI were also unrelated to this endpoint, and
only increasing age and decreased physical ﬁtness were signiﬁcantly
associated with an increased risk of non-cardiac death.
These ﬁndings were replicated using the categorical Type D ap-
proach based on the cutoff ≥10 on NA and SI scales. Only patients
with Type D (NA ≥ 10 and SI ≥ 10) - but not those with NA or SI only -
had an increased risk of MACE (Fig. 1). Decreased LVEF, poor ﬁtness
and no CABG at baseline were other independent predictors of MACE.
Type Dwas also independently associatedwith increased risk of cardiac
death/MI (OR = 2.49; 95%CI 1.55–3.99, p b .0001) but this was not the
case for NA only (OR = 0.42; 95%CI 0.18–0.99, p = .048) or SI only
(OR = 0.95; 95%CI 0.50–1.79, p = .86). However, the categorical Type
D measure (OR = 1.23; 95%CI 0.57–2.69, p = .60), decreased LVEF,
CABG and PCI did not predict non-cardiac cause of death. Only increas-
ing age (OR= 1.06; 95%CI 1.02–1.10, p = .004) and decreased physical
ﬁtness (OR = 3.90; 95%CI 1.85–8.24, p b .00014) were signiﬁcantly as-
sociated with this endpoint.
3.4. Age as a source of heterogeneity
We repeated the analysis for MACE in the four pre-speciﬁed age
subgroups. Therewere 113 patientswhowere 70 years or older, 522 be-
tween 60 and 69, 569 between 50 and 59 and 299 younger than 50. In
this age subgroup analysis, we used the traditional Type D versus non-
Type D dichotomy in order to compare these ﬁndings with the initialCardiac death/MI
(n = 116)
Non-cardiac death
(n = 37)
OR [95% CI] p OR [95% CI] p
1.00 [0.98–1.02] .97 1.06 [1.02–1.10] .004
1.62 [0.80–3.26] .18 0.58 [0.24–1.40] .23
0.93 [0.59–1.48] .76 2.06 [0.94–4.52] .071
2.27 [1.49–3.44] b .0001 0.96 [0.44–2.09] .91
1.95 [1.29–2.94] .001 3.80 [1.80–8.03] b .0001
0.33 [0.19–0.55] .0001 0.81 [0.34–1.92] .63
0.56 [0.34–0.92] .02 0.49 [0.19–1.28] .15
1.02 [0.82–1.27] .86 0.88 [0.59–1.31] .53
1.21 [0.98–1.50] .08 1.33 [0.93–1.90] .12
1.25 [1.05–1.49] .01 1.19 [0.86–1.65] .29
ial infarction; NA= negative affectivity; PCI = percutaneous coronary intervention; SI =
gniﬁcant at p b .05 level
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Fig. 2. Association of Type D versus non-Type D personality with MACE in 4 different age
groups. Note: MI = myocardial infarction. M =mean.
Major Adverse Cardiac Events (n=295)
Age (years)
Male gender
Index MI at baseline
Decreased LVEF*
Poor exercise tolerance † 
No CABG at baseline
No PCI at baseline
High SI / Low NA
High NA / Low SI
High NA / High SI (Type D)
OR=0.99 [0.98 -1.01] p=0.20
OR=0.98 [0.65 -1.48] p=0.91
OR=0.93 [0.68 -1.28] p=0.67
OR=1.45 [1.07 -1.97] p=0.017
OR=1.77 [1.34 -2.34] p<0.0001
OR=2.50 [1.74 -3.60] p<0.0001
OR=1.23 [0.88 -1.72] p=0.23
OR=0.78 [0.52 -1.17] p=0.24
OR=0.63 [0.40 -0.99] p=0.044
OR=1.82 [1.33 -2.50] p<0.0001
Fig. 1.Multivariable predictors of MACE, using the categorical Type D approach. Note: * Left ventricular ejection fraction ≤50%. † ≤140/≤120 W for younger/older men; ≤100/≤80 W for
younger/older women. CABG = coronary artery bypass graft surgery; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NA = negative affectivity; PCI =
percutaneous coronary intervention; SI = social inhibition.
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patients with high NA/low SI, high SI/low NA, or low on both NA and SI
were pooled in one non-Type D reference group. There was a dose–
response relationship between Type D personality and incidence of ad-
verse events, with the risk increasingwith decreasing age (Fig. 2). In the
aged over 70 subgroup, Type Dwas not associatedwithMACE (p= .57),
but in the younger age subgroups, Type Dwas predictive ofMACE (Aged
60–69, p = .001; Aged 50–59, p b .0001; Aged below 50, p = .002).
Multivariable analyses showed that not receiving CABG treatment was
the only signiﬁcant predictor ofMACE in the oldest age group, while de-
creased LVEF, poor exercise tolerance, no CABG at baseline, and Type D
personality were all independently associated with MACE in the
middle-aged group (Table 3). Remarkably, Type D personality was the
only signiﬁcant predictor of MACE in the subgroup aged below
50 years (Table 3, last column).
4. Discussion
The current study aimed to examine the effects of two potential
sources of heterogeneity affecting the association between Type D per-
sonality and adverse events in patients with CAD. Results indicated that
both the choice of endpoint (i.e. cardiac mortality/MI vs. non-cardiac
mortality) and the age distribution of the sample signiﬁcantly impacted
risk estimates of adverse events associated with Type D personality.
The selection of endpoints is very important in clinical trials and ep-
idemiological studies [33]. The current study comparedMACEwith car-
diac death/MI and non-cardiac death, with the latter comparison being
of utmost importance. Although studying all-causemortality has practi-
cal advantages (e.g., easy to assess, no interpretation biases), it can di-
lute the signiﬁcance of risk factors whose mechanistic pathways affect
disease-speciﬁc causes of death [17]. Studying cardiac death/MI brings
higher sensitivity to the risk factor effect, and resistance to inﬂuence
of random variations in other outcomes that are unlikely to be affected
by the risk factor [17]. These factors may explain the currently observed
differential effect of TypeD personality on cardiac vs. non-cardiac death.
The biological mechanistic pathways that have been associated with
Type D personality are disease-speciﬁc and involve increased coronary
plaque severity [34,35], higher macrophage activity [36], increased
pro-inﬂammatory activation [37] and oxidative stress [38], endothelial
dysfunction [39,40], increased daytime cortisol output [41], alteredcardiovascular stress reactivity [42,43], and acute stunning of the myo-
cardium in response to stress [44]. These ﬁndings support the biological
plausibility of TypeD as a cardiac riskmarker, and indicate that the Type
D-associated risk estimate, which is hypothesized to work through
disease-speciﬁc pathways, may become diluted when examining all-
cause mortality in a cardiac population. Accordingly, Type D was unre-
lated to non-cardiac death in the current sample of patients with CAD,
which may partly explain the null ﬁndings in Type D studies that used
all-cause mortality as an endpoint [10–13]. Depression also failed to
predict all-cause mortality in the majority of negative Type D studies
[11–13], suggesting that the choice of endpoint may be important for
psychosocial factors in general.
The other pre-speciﬁed subgroup analysis concerned age as an effect
modiﬁer. Previous studies have shown that older patients already have
a highermortality risk compared to younger patients, due tomyocardial
ageing (i.e. cellular processes), more medical comorbidities, and
decreased treatment choices [19–21]. The present ﬁndings show that
Type D predicted MACE and cardiac death/MI in the aged below 70
subgroup, but not in the patients aged 70 or higher. By analogy, a number
Table 3
Risk estimates for MACE, stratiﬁed by older, middle-aged and younger age groups.⁎
70 years or older
(m = 74 ± 3.9 y)
n = 113
Between 50 and 69 years
(m = 59 ± 5.4 y)
n = 1091
Below 50 years
(m = 44 ± 4.5 y)
n = 299
OR [95% CI] p OR [95% CI] p OR [95% CI] p
Clinical covariates
Decreased LVEF (b50%) 1.65 [0.55–4.99] .38 1.56 [1.09–2.25] .016 1.05 [0.55–2.03] .88
Poor exercise tolerance 2.50 [0.71–8.81] .16 1.85 [1.33–2.56] b .0001 1.44 [0.79–2.65] .24
No CABG at baseline 4.24 [1.23–14.65] .022 2.44 [1.66–3.58] b .0001 1.93 [0.94–3.96] .074
No PCI at baseline 0.87 [0.25–2.95] .82 1.34 [0.89–2.02] .17 1.08 [0.55–2.11] .83
Dichotomous Type D measure
NA ≥ 10 and SI ≥ 10 (Type D) 1.43 [0.43–4.80] .57 2.20 [1.59–3.03] b .0001 2.27 [1.31–3.95] .004
CABG= coronary artery bypass surgery; MACE=major adverse cardiac event; MI =myocardial infarction; NA= negative affectivity; PCI = percutaneous coronary intervention; SI =
social inhibition. Bold = signiﬁcant at p b .05 level; Italic = signiﬁcant at trend level (p b .10)
⁎ Multivariable logistic regression models with all variables entered simultaneously.
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age about 10 years older as compared to the patients thatwere included
in the present analyses [24–27]. Studies that also used the 70 years of
age breakdown in cardiac patients showed a) that mortality risks
differed in the ≥70 group versus the younger group [45], and b) that,
as was the case with Type D in the current study, depression predicted
adverse events in younger but not in older patients [46]. Hence, it is
possible that CAD patients with depression or Type Dwho die at an ear-
lier age may be more vulnerable to stress-related cardiac events than
those who survive to old age [15]. Moreover, research has repeatedly
shown that younger patients have a different risk proﬁle, clinical pre-
sentation, prognosis and experience more pronounced psychological
and social effects [47,48]. Aging may be accompanied by a gradual cog-
nitive decline, mostly with respect to memory and cognitive processing
speed [49], aswell as by changes in personality [50,51]. A recent study in
patients with CAD, showed that Type D personality was associated with
worse cognitive performance, independent of clinical measures of dis-
ease severity [52]. In patients with CAD, cognitive impairment has also
been related to increased mortality risk [53]. Hence, accelerated cogni-
tive decline, as a marker of advancing biological aging, could serve as
one of the explanatory mechanisms linking Type D personality with
increased mortality risk at relatively earlier ages [54]. Nonetheless, at
later ages, medical comorbidities might play a more prominent role in
explaining increased mortality than personality. Overall, these age
group speciﬁc ﬁndings further corroborate the notion that age may
moderate the risk estimates associated with psychosocial risk factors.
Ourﬁndings should be interpretedwith appropriate caution because
this is a re-analysis of 4 combined CAD cohorts. However, re-analyses
are not uncommonwhen studying effectmodiﬁers, and secondary anal-
yses of clinical trials such as ENRICHD (e.g., [55,56]) have also addressed
this issue. All patients were recruited from a cardiac rehabilitation
program in a single universitymedical center, whichmay limit general-
izability. Most patients were men with CAD and our ﬁndings may not
generalize to women with CAD or to patients with other cardiac condi-
tions. Future studies should include more women in order to examine
sex differences in Type D related mortality, its predictors and its effect
moderators. Finally, the use of different Type D measures is a limitation
of this pooleddata set. Strengths of this re-analysis include the relatively
large number of events in the combined dataset, and the theory-based
and predeﬁned subgroup analyses.
To better understand the interactive networks of risk factors in-
volved in CAD incidence and progression, amore subtle and sophisticat-
ed approach is required from future research. In addition to complicated
network analyses, this involves the search for moderators revealing at
what ages, or in what subgroups and for what outcomes risk factor
associations hold [15]. Other moderator analyses that have been
performed to date suggest moderator effects of disease severity [57],
sex, and ethnicity [58] on mortality in CAD patients. Clinically, this is
important as well. Taking sources of heterogeneity into considerationmay be useful to improve effectiveness of personalized interventions
aimed at reducing the risk for adverse health outcomes conferred by
Type D [59,60].
In summary, our ﬁndings indicate that research should account for
the circumstances under which risk factors, in this case Type D, but
also other psychological risk factors [46], may have an adverse effect
on cardiac outcomes. Type D consistently predicted adverse events in
patients with MACE or cardiac death/MI while Type D personality had
no effect on non-cardiac death or in older patients with CAD. Overall,
these ﬁndings suggest that heterogeneity in study and sample charac-
teristics may at least partly explain mixed ﬁndings in Type D research,
and research on CAD needs to consider psychosocial factors whose
mechanistic pathways are likely to affect the cardiovascular system.
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